Evotec's Partner Forge Therapeutics Receives Prestigious CARB-X Research Award


Forge will receive an initial award of $ 4.8 m over 15 months and potentially up to $ 4.0 m from CARB-X after that period upon achievement of certain milestones. CARB-X, launched in August 2016, is one of the world's largest public-private partnerships focused on pre-clinical discovery and development of new antimicrobial products.



from Biotech News